Abstract

Background
Hematopoietic stem cell transplantation (HSCT) has been proposed as a therapeutic option for patients with Systemic Lupus Erythematosus (SLE) refractory to standard therapy. This therapeutic approach has been applied to other severe autoimmune diseases refractory to standard therapy with promising results.
Aim
To systematically review the literature and analyze the available evidence on HSCT therapy in patients with SLE and antiphospholipid syndrome (APS), with a focus on therapy efficacy and occurrence of adverse events.
Methods
A detailed literature search, applied to Ovid MEDLINE, In-Process and Other Non-Indexed Citation and Ovid Medline 1986 to 2014, has been developed a priori to identify articles that reported findings from clinical and laboratory studies that investigated the effect of HCT in patients with SLE.
Results
25 studies met all inclusion criteria, including a total of 279 SLE patients; of those, 54 patients also fulfilled the classification criteria of APS. The majority of the studies reported an improvement after HSCT in terms of diseases activity control (assessed with SLEDAI, or time-free from diseases) or overall survival. However, one study reported no net benefit of HSCT when compared to immunosuppression alone. One retrospective study reported an overall survival at 5 years of 81% in 28 SLE patients.
Of note, 5 cases (9.3%) of aPL negativization were reported after HSCT in the APS patients. When combining these studies and analyzing these patients with APS, 32 out of 44 (73%) were able to discontinue anticoagulation after HSCT. Our findings also demonstrate a total of 86 infections in the pool of patients (30.8%), 3 of which resulted in the death of the patient (1.3%). We observed an annual incidence of infection of 11.9% with a mean follow up of 36.2 months.
Conclusion
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Preliminary results of HSCT as a therapeutic option for SLE appear promising. Further studies are warranted in order to assess the safety of the procedure for both the occurrence of secondary autoimmune disease and the rate of infection. However, the rate of adverse effects confines this option to very selected cases of SLE patients resistant or refractory to standard approaches.
Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by a relapsing intermitting course with periods of flares, alternating periods of remission and by highly heterogeneous clinical manifestations with a multi-systemic involvement [1] . The management of SLE is based on nonsteroidal anti-inflammatory drugs, glucocorticoids (GC), hydroxychloroquine (HCQ) and immunosuppressive agents, as well as novel biotechnological therapies [2, 3] . Although advances in the treatment of SLE have led to a significant improvement in the prognosis, SLE management remains challenging due to the adverse effects associated with conventional therapies and the occurrence of refractory disease.
Hematopoietic stem cell transplantation (HSCT) has been proposed as an alternative therapeutic option for SLE patients refractory to standard therapy. The initial findings of remission of severe autoimmune disease were described in patients undergoing transplantation for a hematologic disease who also had a coincidental autoimmune disease [4] [5] [6] . Following these observations, this therapeutic approach has been applied to other severe autoimmune diseases refractory to standard therapy [7] [8] [9] [10] and preliminary results of animal model studies have been promising [11, 12] . Although the mechanism of remission of disease induced by HSCT is likely to be due to intensive immune suppression, it may also play a role in modifying the immune system after transplant and thus leading to a prolonged period of remission.
In this systematic review, we aim to analyze the available evidence on HSCT therapy in patients with SLE and antiphospholipid syndrome (APS), focusing on therapy efficacy and occurrence of adverse events. All published studies in manuscript form enrolling at least 1 patient with SLE undergoing auto-or allogenic HCT were included. We excluded abstracts not published as full manuscripts. Studies were independently reviewed by 2 authors (AL and AA). Any disagreements were resolved by consensus with other authors (SS, MR, MK).
Patients and Methods
Search and Study Selection
Data Collection
Data were collected on study details, patient characteristics, clinical outcomes [overall survival (OS)] and harms [transplantation-related morbidity (TRM), disease relapse, autoantibodies seroconversion].
Methodological quality utilizing a standardized data extraction form (Appendix 1). All data were independently extracted by 2 authors (AL and AA). Extracted data was verified for accuracy by another author (SS.). Methodological quality of included cohort studies was assessed using the Newcastle-Ottawa scale modified for single-arm cohort [13] .
Data Analysis and Statistical Methods
A proportion was calculated for each outcome. When possible, effect estimates from studies similar in terms of study design, included patients, interventions, and outcomes were pooled together. All results are reported as a proportion and a 95% confidence interval (CI). Heterogeneity was tested using the I 2 test. An I 2 above 30% was considered moderate heterogeneity and above 60% was considered high heterogeneity.
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This systematic review is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [14].
Results
Search Results and Characteristics of Included Studies
The search identified 2088 studies and 25 met all inclusion criteria . The study selection process is reported in Figure 1 . The use of allogenic/auto-HCT as rescue therapy for SLE/SAPS was assessed using data from 2 prospective [15, 36] , 10 retrospective studies [16] [17] [18] [19] [20] [21] [22] [23] 34 ]and 13 case reports [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] 35, [37] [38] [39] , for a total of 279 SLE patients. Of those, 54 patients also fulfilled the criteria of APS. The demographic and pretransplant clinical characteristics of the patients of included studies are reported in Tables 1 and 2 for patients with SLE and for SLE and APS, respectively.
Control of disease activity
3 out of 12 studies (2 prospective and 10 retrospective) assessed SLE activity with SLE Disease Activity Index (SLEDAI) [15, 18, 20] . Traynor and colleagues [15] reported that following HSCT a gradual, but marked, improvement in their cohort (<5 of SLEDAIin 12 patients). Gualandi et al. [18] demonstrated that 5 SLE patients had a decrease from 90 of cumulative SLEDAI index to 9 after transplant. Whereas another study [20] reported an overall decrease of SLEDAI after either immunosuppression alone or followed by transplant, with no statistical difference between the two groups.
4 studies reported the disease-free survival in their cohort of patients [17, 21, 23, 34] . Vanikar et al. [17] reported a disease-free interval of 7.35 months; Alchi et al. [23] showed a 5 year disease-free survival of 29%; Song et al. [21] reported a progression-free survival of 64.7% (significantly higher than the control group), and finally Burt et al. [34] described a 50% disease-free survival at 5 years.
aPL profile changes after HSCT
It is worth noting that studies that included SLE patients with APS (SAPS), reported 4 cases (7.4%) of aPL negativization after transplant and one study reported one case (1.9%) of aPL negativization after transplant in the first 6 months of follow-up. Statkute et al. [37] stated that 14 out of 22 SAPS patients were able to discontinue anticoagulation, while Burt et al. [34] described 18 out of 22 SAPS patients that were able to stop anticoagulation therapy after transplant. No APS-related recurrences were described during the follow up (range=8-29 months).
Overall-survival and mortality
One retrospective study out of twelve total studies [23] reported the 5 years overall survival outcome. Alchi et al. [23] reported that in their 28 SLE patients the OS was 81% (5 patients died in 2 years after treatment, 3 deaths were caused by infections, 1 progressive SLE and 1 caused by autoimmune haemolytic anaemia).
Burt et al observed in 50 SLE patients a disease-free survival at 5 years of 50% (2 patients died after mobilization: one active lupus and one and one from mucormycosis).
Song et al [21] , reported that in their study of 17 SLE patients there were 2 deaths during the follow up period of 89 months. Paquini et al [22] , with a cohort of 27 SLE patients, reported 8 deaths in a follow up period of 31 months and lastly Loh et al. [16] reported 3 deaths (2 SLE progression and the third following an accident). Furthermore, a case report described the death of all three of these patients due to transplant related complications during the follow up of 60 months [30] .
Twenty studies did not report deaths during their follow-up period (range= 7-70 months).
When pooling together these studies, we observed an overall mortality of 8.3% with a mean follow-up of 36.2 months.
The heterogeneity between studies was high (I 2 = 87%).
The results describing outcomes, mortality and post-transplant clinical characteristics of the patients included in the analysis are summarized in Table 3 and 4.
Adverse events (AEs)
In the 25 studies included, we observed a total of 86 infections (30.8%), 3 of which resulted in the death of the patient (1.3%). When pooling together the results from the studies analyzed, there was an annual incidence of infections of 11.9% with a mean follow up of 36.2 months. Other adverse events included one case of allergic reaction to cyclophosphamide (0.4%), one case of fever related to G-CSF (0.4%), one Epstein
Barr-associated lymphoproliferative disorder, one case of angular chelitis (0.4%), one case of factor VIII inhibitor hemorrhage (0.4%), two cases of secondary autoimmune diseases (0.7%) (one case of autoimmune hemolytic anemia that caused the death of the patient and one acquired hemophilia), three cases of bone pain (1.1%), three cases of mucositis (1.1%), three cases of (1.1%) enteropathy and finally three cases of severe hemorrhage (1.1%).
Discussion
Conventional treatments for SLE are typically directed against the adaptive immune response by limiting T and B cell activation, and/or lowering auto-antibody production. The rationale behind HSCT therapy in SLE is based on an initial phase of intensive immune-suppression to ablate the auto-reactive lymphocytes. The second phase is represented by a repopulation of the immune system by transplant with either autologous or allogeneic hematopoietic CD34+ progenitors cells, rescuing the patient from severe cytopenia and/or hematopoietic failure. It has been hypothesized that HSCT might permanently alter the immune system composition by losing T cell-mediated immune memory [4, 9] . Although preliminary results described in the literature are promising, it is not clear whether HSCT alone with no intensive immunosuppression regimen could potentially induce remission in SLE patients. Currently, there is only one prospective phase I study that has investigated the safety and efficacy of immune suppression and HSCT in the treatment of SLE [15] .
Although all patients included in the study demonstrated a gradual, but marked improvement (both in terms of clinical and laboratory parameters) it is important to note that phase I studies are not powered to determine efficacy of new experimental therapies.
Interestingly in the studies analysed, antibody negativization occurred in some of patients both for anti-DNA antibodies and antiphospholipid antibodies (aPL). Conversely, aPL negativization following immunosuppression therapy have been only occasionally described [40] . Besides, it is important to note that out of 44 APS reported cases for whom detailed therapy was provided, more than 70% were able to discontinue anticoagulation after HSCT [34, [36] [37] [38] .
There are several limitations to the studies analysed: low number of patients of the studies included, potential publication bias with studies reporting only positive outcomes, heterogeneity in clinical presentation, and applied protocols of both immunosuppression and HSCT. It is also important to note a high number of infections and adverse events occurred in patients that underwent the protocol of high dose immune suppression regimen followed by HSCT. In fact, the protocol of intense immunosuppression applied to the treatment is intended to ablate the immune system to the point of marrow suppression, and the related adverse events can't be underestimated.
A further obstacle to this therapy, as described by Daikeler and colleagues [41] , is the development of secondary autoimmune diseases that may occur after HSCT. In this retrospective study, after autologous HSCT for primary autoimmune diseases, 29 of 347 patients analysed, developed at least one secondary autoimmune disease in the follow up period, and after allogeneic HSCT, 3 of 16 patients. Even though in our analysis only two cases of secondary autoimmune disease were described, Daikeler et al identified, after multivariate analysis, an initial diagnosis of SLE (P =0.019; hazard ratio=3.21; 95% confidence interval, 1.21-8.48) is significant risk factor for developing a secondary autoimmune disease after HSCT.
Conclusion
Despite the limitations of the studies analysed, the preliminary results of intense immunosuppression and HSCT seem promising. Further studies are warranted in order to assess the safety of the procedure both for occurrence of secondary autoimmune diseases and rate of infection. Prior to considering HRCT as a novel and viable therapeutic option, randomized prospective trials are advised in order to determine the efficacy of HSCT alone and its contribution in inducing remission in SLE and APS patients. Meng et al. [20] 2011 SLESAI scores after treatment either by transplantation or by immunosuppressive therapy decreased dramatically when compared to that before treatment, although there was no significant difference between the two groups. However, the rate of maternal HTN and lupus nephritis of mother was greatly reduced in autologous peripheral blood stem cell transplanted group compared to non-transplanted group. Additionally, the outcome of lupus flare activity of the mother after delivery is significantly better in transplanted group. 
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